oral semaglutide approval Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) FDA Approves GLP-1 Pill for

If an employee is pursuing a GLP-1 related health change without resistance training or enough protein, there can be consequences for stamina and strength

Mechanistically, the common thread appears to be dampening drug-evoked dopamine signaling in the nucleus accumbens and engaging GLP-1 anti-craving circuits involving the VTA, nucleus accumbens, lateral septum, laterodorsal tegmentum, and nucleus tractus solitarius

That said, individual targets may vary and should be discussed with your clinician

Compounded semaglutide typically has a Beyond-Use Date (BUD) ranging from 30 to 90 days, depending on the specific pharmacys formulation and testing